Growth hormone treatment and risk of malignancy.

Growth hormone treatment and risk of malignancy.

Item
http://www.wikidata.org/entity/Q35171723
Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study.The relationship between serum levels of prolactin and growth hormone in the early postnatal period.Mortality and cancer incidence among patients treated with recombinant growth hormone during childhood in Israel.Advances in paediatrics in 2016: current practices and challenges in allergy, autoimmune diseases, cardiology, endocrinology, gastroenterology, infectious diseases, neonatology, nephrology, neurology, nutrition, pulmonology.The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects.aPKCζ-dependent Repression of Yap is Necessary for Functional Restoration of Irradiated Salivary Glands with IGF-1.The effect of a 10-week Nordic walking training program on the level of GH and LH in elderly women.
P2860

Growth hormone treatment and risk of malignancy.

Item
http://www.wikidata.org/entity/Q35171723
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Growth hormone treatment and risk of malignancy.
@ast
Growth hormone treatment and risk of malignancy.
@en
type
label
Growth hormone treatment and risk of malignancy.
@ast
Growth hormone treatment and risk of malignancy.
@en
prefLabel
Growth hormone treatment and risk of malignancy.
@ast
Growth hormone treatment and risk of malignancy.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Growth hormone treatment and risk of malignancy.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P932